• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

    11/14/24 5:48:35 PM ET
    $SCPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPH alert in real time by email
    SC 13G/A 1 tm2427620d16_sc13ga.htm SC 13G/A

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

    ScPharmaceuticals Inc.

    (Name of Issuer)

     

    Common stock, $0.0001 par value per share

    (Title of Class of Securities)

     

    810648105

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨

     

    x

     

    ¨

    Rule 13d-1(b)

     

    Rule 13d-1(c)

     

    Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No.   810648105
    1.

    Names of Reporting Persons

    Lundbeckfond Invest A/S (“Lundbeckfond”)

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ¨ (b) x (1) 

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Denmark

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    2,863,987

    6.

    Shared Voting Power

    0

    7.

    Sole Dispositive Power

    2,863,987

    8.

    Shared Dispositive Power

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,863,987

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.7% (2)

    12.

    Type of Reporting Person (See Instructions)

    CO

           

    (1)All of such shares are Common Stock and held of record by Lundbeckfond. Lene Skole (“Skole”) is the Chief Executive Officer of Lundbeckfond and may be deemed to have sole power to vote and dispose of these shares. The directors of Lundbeckfond have delegated voting and dispositive power with respect to the shares held by Lundbeckfond to Skole.

     

    (2)This calculation is based on 50,028,787 shares of Common Stock outstanding as of August 13, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on August 14, 2024 with the Securities and Exchange Commission (the “SEC”).

     

    2

     

     

    CUSIP No.   810648105
    1.

    Names of Reporting Persons

    Lene Skole (“Skole”)

    2.

    Check the Appropriate Box if a Member of a Group (See Instructions)

    (a)  ¨ (b) x (1)

    3. SEC Use Only
    4.

    Citizenship or Place of Organization

    Denmark

    Number of

    Shares

    Beneficially

    Owned by

    Each

    Reporting

    Person With

    5.

    Sole Voting Power

    2,863,987

    6.

    Shared Voting Power

    0

    7.

    Sole Dispositive Power

    2,863,987

    8.

    Shared Dispositive Power

    0

    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

    2,863,987 shares of common stock

    10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)    ¨
    11.

    Percent of Class Represented by Amount in Row (9)

    5.7% (2)

    12.

    Type of Reporting Person (See Instructions)

    IN

           

    (1)All of such shares are Common Stock and held of record by Lundbeckfond. Skole is the Chief Executive Officer of Lundbeckfond and may be deemed to have sole power to vote and dispose of these shares. The directors of Lundbeckfond have delegated voting and dispositive power with respect to the shares held by Lundbeckfond to Skole.

     

    (2)This calculation is based on 50,028,787 shares of Common Stock outstanding as of August 13, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on August 14, 2024 with the SEC.

     

    3

     

     

    Item 1.
      (a)

    Name of Issuer

    ScPharmaceuticals Inc.

      (b)

    Address of Issuer’s Principal Executive Offices

     

    25 Mall Road, Suite 203

    Burlington, MA 01830

     
    Item 2.
      (a)

    Name of Person Filing

     

    This Schedule 13G is being filed on behalf of each of the following persons:

     

    Lundbeckfond Invest A/S (the “Lundbeckfond”)

     

    Lene Skole (“Skole”)

     

    The foregoing entities and individuals are collectively referred to as the “Reporting Persons.”

    Skole is the chief executive officer of Lundbeckfond. The directors of Lundbeckfond have delegated voting and dispositive power with respect to shares held by Lundbeckfond to Skole.

      (b)

    Address of Principal Business Office or, if none, Residence

     

    The business address for each Reporting Person is:

     

    c/o Lundbeckfond Invest A/S

    Scherfigsvej 7

    DK-2100 Copenhagen, Denmark

      (c)

    Citizenship

     

    Lundbeckfond is a private Danish corporation.

     

    Skole is a citizen of Denmark.

     

      (d)

    Title of Class of Securities

    Common Stock, $0.0001 par value (“Common Stock”)

      (e)

    CUSIP Number

    810648105

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
       
      Not applicable
     
    Item 4. Ownership

     

    (a) Amount beneficially owned: See row 9 of cover page for each Reporting Person.

    (b) Percent of class: See row 11 of cover page for each Reporting Person.

    (c) Number of shares as to which the person has:

     

    (i) Sole power to vote or to direct the vote:

     

    See row 5 of cover page for each Reporting Person.

     

    (ii) Shared power to vote or to direct the vote:

     

    See row 6 of cover page for each Reporting Person.

     

    (iii) Sole power to dispose or to direct the disposition of:

     

    See row 7 of cover page for each Reporting Person.

     

    4

     

     

    (iv) Shared power to dispose or to direct the disposition of:

     

    See row 8 of cover page for each Reporting Person.

     

    The percentage of common stock reported as beneficially owned by the Reporting Persons is based upon 50,028,787 shares of common stock outstanding as of August 13, 2024, as reported in the Issuer’s Quarterly Report on Form 10-Q filed on August 14, 2024 with the Securities and Exchange Commission.  

     

    Item 5. Ownership of Five Percent or Less of a Class
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following   ¨
     
    Item 6. Ownership of More than Five Percent on Behalf of Another Person
       
      Under certain circumstances set forth in the governing documents of Lundbeckfond, the stockholders of Lundbeckfond may be deemed to have the right to receive dividends from, or the proceeds from, the sale of shares of the Issuer.
     
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
       
      Not applicable
     
    Item 8. Identification and Classification of Members of the Group
       
      Not applicable
     
    Item 9. Notice of Dissolution of Group
       
      Not applicable
     
    Item 10. Certification
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    5

     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

    LUNDBECKFOND INVEST A/S

     

    By:  /s/ Christian Elling  
      Name:  Christian Elling  
      Title:    Managing Partner  
       
    /s/ Lene Skole  
    LENE SKOLE, CEO  

     

    6

     

     

    Exhibit(s):

     

    1Joint Filing Agreement

     

     

     

    Get the next $SCPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SCPH

    DatePrice TargetRatingAnalyst
    9/7/2023$20.00Buy
    Craig Hallum
    12/1/2022$25.00Outperform
    Cowen
    10/21/2022$14.00Buy
    Jefferies
    10/11/2022$11.00Mkt Perform → Outperform
    SVB Leerink
    8/2/2022$10.00Buy
    Maxim Group
    9/9/2021$6.00Market Perform
    SVB Leerink
    More analyst ratings

    $SCPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/15/24 4:06:50 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/14/24 5:48:35 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by scPharmaceuticals Inc.

      SC 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      11/14/24 3:58:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Craig Hallum initiated coverage on scPharmaceuticals with a new price target

      Craig Hallum initiated coverage of scPharmaceuticals with a rating of Buy and set a new price target of $20.00

      9/7/23 9:06:27 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on scPharmaceuticals with a new price target

      Cowen initiated coverage of scPharmaceuticals with a rating of Outperform and set a new price target of $25.00

      12/1/22 7:54:00 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on scPharmaceuticals with a new price target

      Jefferies resumed coverage of scPharmaceuticals with a rating of Buy and set a new price target of $14.00

      10/21/22 7:40:23 AM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Leadership Updates

    Live Leadership Updates

    See more

    $SCPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SCPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $SCPH
    SEC Filings

    See more

    $SCPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $SCPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Lantheus Announces Appointment of Minnie Baylor-Henry as New Board Member

      NORTH BILLERICA, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("the Company") (NASDAQ:LNTH), today announced the appointment of Ms. Minnie Baylor-Henry, Esq., a renowned expert in regulatory affairs and compliance in the life sciences industry, to Lantheus' Board of Directors ("Board"), effective immediately. As an independent director, Ms. Baylor-Henry will serve as a member of the Board's Compensation Committee and the Science and Technology Committee. Following the appointment of Ms. Baylor-Henry, the Board will be comprised of nine directors, eight of whom are independent. "We are pleased to welcome Minnie Baylor-Henry, a highly respected authority in FDA law an

      3/1/22 4:05:00 PM ET
      $APYX
      $LNTH
      $PRTK
      $SCPH
      Medical/Dental Instruments
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Biotechnology: Pharmaceutical Preparations
    • President and CEO Tucker John H gave a grant of 200,000 shares, decreasing direct ownership by 31% to 440,847 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      2/12/25 4:32:59 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Nokes Rachael was granted 88,445 shares, increasing direct ownership by 131% to 156,061 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      2/12/25 4:27:03 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and Treasurer Nokes Rachael covered exercise/tax liability with 5,235 shares, decreasing direct ownership by 7% to 67,616 units (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      1/7/25 4:30:06 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Large owner Orbimed Advisors Llc bought $2,000,000 worth of shares (500,000 units at $4.00) (SEC Form 4)

      4 - scPharmaceuticals Inc. (0001604950) (Issuer)

      8/15/24 4:51:14 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by scPharmaceuticals Inc.

      SCHEDULE 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)

      4/28/25 4:01:03 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by scPharmaceuticals Inc.

      DEFA14A - scPharmaceuticals Inc. (0001604950) (Filer)

      4/21/25 4:12:38 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by scPharmaceuticals Inc.

      DEF 14A - scPharmaceuticals Inc. (0001604950) (Filer)

      4/21/25 4:10:57 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

      BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first quarter 2025 and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website,

      5/7/25 4:01:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Announces Participation in Three Upcoming Investor Conferences

      BURLINGTON, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that John Tucker, President and Chief Executive Officer, will participate in the following upcoming investor conferences: The Citizens Life Sciences Conference: Presentation on Wednesday, May 7 at 9:30 a.m. ET.Craig-Hallum 22nd Annual Institutional Investor Conference: Wednesday, May 28, Investor Meetings OnlyH.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ: Presentation on May 20 at 10:00 a.m. ET. A webcast of the presentations

      5/1/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

      3/19/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FUROSCIX issued to SCPHARMACEUTICALS INC

      Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form

      10/11/22 1:54:57 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SCPH
    Financials

    Live finance-specific insights

    See more
    • scPharmaceuticals to Announce First Quarter 2025 Financial Results After the Market Close on May 14, 2025

      BURLINGTON, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, May 14, 2025, to discuss the financial results for the first quarter 2025 and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the Company's website,

      5/7/25 4:01:44 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      scPharmaceuticals generated fourth quarter 2024 net FUROSCIX® revenue of $12.2 million, and full year 2024 revenue of $36.3 million Cash and cash equivalents of $75.7 million as of December 31, 2024 U.S. Food and Drug Administration (FDA) approved the FUROSCIX expanded label indication to include the treatment of edema due to fluid overload in patients with chronic kidney disease scPharmaceuticals to host investor conference call and webcast today, Wednesday, March 19th, at 4:30pm ET BURLINGTON, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through pat

      3/19/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • scPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025

      BURLINGTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company committed to revolutionizing cardiorenal healthcare through patient-centric innovations, today announced that scPharmaceuticals management will host a conference call and audio webcast at 4:30 p.m. ET on Wednesday, March 19, 2025, to discuss the financial results for the fourth quarter and full year 2024, and provide a business update. Registration and access for the conference call can be completed through this direct registration link. The live webcast and replay of the conference call can be accessed here or under "News & Events" in the Investor Relations section of the

      3/12/25 4:01:00 PM ET
      $SCPH
      Biotechnology: Pharmaceutical Preparations
      Health Care